3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Glioma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Paraproteinemias
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hematologic Diseases
1
Gliosarcoma
1
Glioblastoma
1
Interventions
pembrolizumab
25
Cyclophosphamide
20
Nivolumab
13
Doxorubicin
13
Carboplatin
10
Surveys and Questionnaires
9
Paclitaxel
9
Exercise
9
atezolizumab
8
Vincristine
8
Rituximab
8
Radiotherapy
8
Prednisone
8
Dexamethasone
8
Bevacizumab
8
venetoclax
7
fludarabine
7
Pemetrexed
7
Fluorouracil
7
Docetaxel
7
Blood Specimen Collection
7
lenvatinib
6
dostarlimab
6
cemiplimab
6
budigalimab
6
Oxaliplatin
6
Cisplatin
6
durvalumab
5
Leucovorin
5
Lenalidomide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neoplasms
×
CLR1404
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled